GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nanologica AB (publ) NICA.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

0.17

-1.18%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Nanologica AB (publ)

Its shares trade on Nasdaq Stockholm under the ticker NICA.ST. It has been listed since 30 October 2015. In the fiscal year to 31 December 2025, it reported revenue of SEK 21.1m and a net loss of SEK 51.3m. At that date it held total assets of SEK 88.1m and shareholders' equity of SEK 22.6m.

Nanologica AB engages in the research and development of pharmaceutical products. The company is headquartered in Sodertalje, Stockholm. The company went IPO on 2015-10-30. The firm specializes in developing nanoporous materials from nanoporous silica (silicon dioxide) for a variety of applications, ranging from purification to pharmaceutical excipients. The firm's core competency has been developed and expanded in two areas of application, in particular: Drug Delivery and Chromatography, a technology used for the separation and purification of products on the market and in development. The firm's Drug Delivery sector operates within a niche domain of nanocarriers. Nanologica AB (publ)’s drug delivery technology is aimed on absorption of the medicine by the body for drugs that are poorly soluble in water.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
30 Oct 2015

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Nanologica AB specializes in nanoporous silica for pharmaceutical applications.
  • The company focuses on drug delivery for poorly soluble water-based medicines.
  • Nanologica AB's core competency in chromatography separates and purifies products.

Weaknesses

  • Nanologica AB's IPO was on 30 October 2015.
  • The company operates in a niche domain of nanocarriers.
  • Nanologica AB is headquartered in Sodertalje, Stockholm.

Opportunities

  • Nanologica AB's drug delivery technology targets poorly soluble water-based medicines.
  • The firm's chromatography technology is used for market and development products.
  • Nanologica AB's nanoporous silica materials have diverse applications.

Threats

  • Nanologica AB's business is limited to pharmaceutical R&D.
  • The company's focus on nanocarriers may restrict market expansion.
  • Nanologica AB's operations are confined to Sodertalje, Sweden.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.